| Pack Size | Single Vial, 10-Pack |
|---|
Tirzepatide (a dual GLP-1/GIP receptor agonist) is a 39-amino-acid synthetic peptide engineered to engage two metabolic receptors at once. The compound carries an unusual mechanism feature — biased agonism toward the GIP receptor relative to GLP-1 — that distinguishes it from balanced dual agonists. Investigators have studied the compound across the SURPASS Phase 3 program in type 2 diabetes (5 trials), the SURMOUNT Phase 3 program in obesity (4+ trials), and 2024–2025 Phase 3 trials extending into MASLD, obstructive sleep apnea, and heart failure with preserved ejection fraction. Each batch carries a Janoshik Analytical Certificate of Analysis covering HPLC purity quantification and MS identity confirmation. The minimum-acceptance threshold is 99 percent purity by HPLC. Supplied as a lyophilized powder in a sealed glass vial, 10 mg per vial. Research-grade laboratory compound; human and veterinary use are excluded.
Description
Tirzepatide is a 39-residue synthetic peptide engineered as a dual receptor agonist for GIP and GLP-1. The molecule's backbone is derived from the native human glucose-dependent insulinotropic polypeptide (GIP) sequence, with engineered modifications that add GLP-1 receptor agonist activity to the GIP-receptor activation native to the parent sequence. Two α-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. A C20 fatty diacid acyl chain attached to lysine-20 through a γ-Glu spacer plus two AEEA (8-amino-3,6-dioxaoctanoic acid) units supports reversible albumin binding, extending plasma half-life to approximately five days.
A foundational mechanism finding from Willard et al. characterised the compound as an "imbalanced and biased" dual agonist (PMID 32730231). Tirzepatide activates GIP receptor with potency comparable to native GIP, but activates GLP-1 receptor with potency lower than native GLP-1. The biased agonism is a real feature of the molecule, not an artifact, and contributes to a pharmacological profile distinct from balanced dual agonists or pure GLP-1 mono-agonists.
The compound was developed by Eli Lilly and brought through one of the largest Phase 3 programs in modern metabolic research. The SURPASS program covered type 2 diabetes glycemic control across multiple comparator arms (SURPASS 1–5). The SURPASS-2 trial in 2021 (PMID 34170647) was a head-to-head comparison against once-weekly semaglutide; investigators reported larger reductions in HbA1c and body weight at all tirzepatide dose tiers compared to semaglutide. SURPASS-4 extended into T2D adults at increased CV risk versus insulin glargine (PMID 34672967). SURPASS-5 examined add-on tirzepatide on top of titrated insulin glargine (PMID 35133415). A SURPASS-3 MRI substudy quantified liver fat and abdominal adipose tissue changes in T2D adults (PMID 35468325).
The SURMOUNT program addressed weight management in obesity. SURMOUNT-2 (PMID 37385275) examined adults with both T2D and obesity. SURMOUNT-4 (PMID 38078870) tested maintenance via a withdrawal design. SURMOUNT-CN (PMID 38819983) extended efficacy data into a Chinese population.
A 2024–2025 wave of Phase 3 trials extended research beyond the original T2D and obesity contexts. The Loomba 2024 NEJM paper documented effects on metabolic dysfunction-associated steatohepatitis with liver fibrosis (PMID 38856224). The Malhotra 2024 NEJM paper (SURMOUNT-OSA) reported reductions in apnea-hypopnea index alongside weight loss in adults with obstructive sleep apnea and obesity (PMID 38912654). The Packer 2025 NEJM paper (SUMMIT) examined heart failure with preserved ejection fraction in adults with obesity (PMID 39555826).
Ronin Peptides supplies tirzepatide as a research-grade lyophilized peptide for laboratory use only. Approved pharmaceutical formulations exist under separate distribution channels — for type 2 diabetes (approved 2022), chronic weight management (approved 2023), and obstructive sleep apnea in adults with obesity (approved 2024). The research-grade compound is not interchangeable with any approved formulation; it is sold strictly for benchwork.
Mechanism in research literature
The compound engages two receptors simultaneously: the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and the GLP-1 receptor (glucagon-like peptide-1 receptor). Both are Gαs-coupled G-protein-coupled receptors — expressed across pancreatic islet cells, gastric tissue, central-nervous-system regions involved in appetite regulation, and various peripheral tissues. Receptor binding raises intracellular cyclic AMP through adenylyl cyclase activation, with downstream signalling that includes glucose-dependent insulin secretion, glucagon suppression, gastric-emptying delay, central appetite modulation, and adipose-tissue-related effects (PMID 36050763, PMID 38388874).
The Willard 2020 mechanism paper documented that tirzepatide's dual agonism is biased and imbalanced. The compound activates GIP receptor with potency similar to native GIP, but activates GLP-1 receptor with potency below native GLP-1 (PMID 32730231). This is the opposite of what naive design intuition would suggest — the molecule is a stronger GIP agonist than GLP-1 agonist, despite the GLP-1 arm receiving more attention in the broader incretin-class research literature. Researchers have proposed that the biased pharmacology contributes to the distinctive effect-size profile observed in SURPASS clinical research, including effects on insulin sensitivity that exceed GLP-1-only agonism.
Thomas and colleagues examined beta-cell function and insulin sensitivity in T2D adults treated with tirzepatide (PMID 33236115). The compound improved both first-phase and second-phase insulin secretion, alongside meaningful improvements in insulin sensitivity by glucose-clamp methodology — a mechanism profile the authors attributed to the dual GIP/GLP-1 receptor engagement.
Pharmacokinetic engineering enables once-weekly subcutaneous dosing. The Aib substitutions at positions 2 and 13 protect against DPP-4 cleavage. The fatty-acid acylation at lysine-20 binds reversibly to serum albumin, holding the compound in circulation. Combined, the modifications produce a plasma half-life of approximately five days — sufficient for once-weekly dosing.
Investigators have continued to study mechanism through the lens of new-indication research. The 2024 SURMOUNT-OSA paper (PMID 38912654) attributed apnea-hypopnea reductions to weight-mediated upper-airway changes. The 2025 SUMMIT paper (PMID 39555826) in HFpEF examined whether tirzepatide-driven weight reduction translates to cardiac functional outcomes; the Packer authors observed improvements in symptom burden and quality-of-life endpoints alongside expected weight reductions.
Studied properties
Type 2 diabetes glycemic control is the foundational research stream. The SURPASS-2 trial (PMID 34170647) compared tirzepatide at 5, 10, and 15 mg/week against once-weekly semaglutide 1 mg in T2D adults. All tirzepatide dose tiers produced larger HbA1c reductions and larger body weight reductions than semaglutide. The 15 mg dose tier reduced HbA1c by approximately 2.30 percentage points versus semaglutide's 1.86 percentage points at 40 weeks. Body weight reduction at the 15 mg dose tier was approximately 11.2 kg versus semaglutide's 5.7 kg.
SURPASS-4 (PMID 34672967) examined T2D adults with established CVD or high CV risk, comparing tirzepatide against insulin glargine over 52 weeks. SURPASS-5 (PMID 35133415) tested tirzepatide as add-on to titrated insulin glargine, demonstrating glycemic improvements without disproportionate hypoglycemia. The SURPASS-3 MRI substudy (PMID 35468325) quantified reductions in liver fat content and abdominal adipose tissue using imaging endpoints.
Body weight reduction in obesity has been characterised across the SURMOUNT program. SURMOUNT-2 (PMID 37385275) reported weight reductions of approximately 12.8 percent in T2D-coexisting adults at 72 weeks. SURMOUNT-4 (PMID 38078870) used a withdrawal design — adults stabilised on tirzepatide were re-randomised to continue or switch to placebo; the placebo arm regained substantial weight, while the continued-tirzepatide arm maintained reduction. SURMOUNT-CN (PMID 38819983) examined Chinese adults with obesity and reported reductions consistent with prior SURMOUNT findings.
A 2024 systematic review and network meta-analysis placed the compound alongside semaglutide in T2D (PMID 38613667). The analysis confirmed the SURPASS-2 head-to-head finding at the broader population level — tirzepatide generally showing larger HbA1c and weight effects than semaglutide at matched dose tiers.
The 2024–2025 Phase 3 program expanded research beyond T2D and obesity. Loomba 2024 in NEJM (PMID 38856224) reported on MASLD with liver fibrosis, with tirzepatide producing reductions in liver fat content and improvements in fibrosis biomarkers at the higher dose tiers. Malhotra 2024 in NEJM (PMID 38912654) reported on obstructive sleep apnea + obesity (SURMOUNT-OSA), with tirzepatide reducing the apnea-hypopnea index by approximately 27.4 events per hour at 52 weeks alongside the expected weight reductions. Packer 2025 in NEJM (PMID 39555826) reported on heart failure with preserved ejection fraction (SUMMIT), with tirzepatide producing improvements in patient-reported symptom burden and quality-of-life scores.
Researchers have characterised tirzepatide's safety profile across SURPASS and SURMOUNT (PMID 36050763, PMID 38388874). Gastrointestinal effects — nausea, diarrhoea, vomiting — are the most common, occurring most prominently during dose escalation and tending to decline with continued exposure. Long-term safety data continues to accumulate as the SURPASS-CVOT trial reports.
Compound specifications
| Specification | Value |
|---|---|
| Common name | Tirzepatide |
| Schema alternate name | Tirzepatide Acetate (chemical-variant designation) |
| Class | Synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist |
| Length | 39 amino acids |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.45 g/mol (free peptide) |
| CAS number | 2023788-19-2 |
| PubChem CID | 156588324 |
| Backbone modifications | Aib substitutions at positions 2 and 13 (DPP-4 resistance); γ-Glu-2×AEEA-C20 fatty diacid acyl group at Lys-20 (albumin binding); backbone derived from native GIP sequence with engineered GLP-1 receptor activity |
| Receptor targets | GIP receptor + GLP-1 receptor (both Gαs-coupled GPCRs); biased toward GIP receptor activation per Willard 2020 |
| Plasma half-life | ~5 days (subcutaneous) |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
Storage and handling
Unopened lyophilized vials hold up well under dry ambient conditions, with usable activity persisting for several weeks even without refrigeration. The unopened original vial is the recommended container until reconstitution. Refrigeration at 2–8 °C extends practical shelf life into months. Long-term archival storage uses −20 °C in a standard laboratory or household freezer.
Keep vials shielded from light, ideally in their original outer packaging. The fatty-acid acylation introduces an oxidation-sensitive feature, so light protection matters more for tirzepatide than for unmodified peptide chains.
After reconstitution, refrigerate the solution at 2–8 °C without delay. Investigators have measured working potency for a reconstituted preparation at typically four to six weeks under refrigeration — at the lower end of the typical peptide working window, since modified incretin-class peptides are more thermally sensitive than simpler peptide chains.
When a research timeline extends past the working window, common practice is splitting the reconstituted solution into single-use volumes immediately after reconstitution and freezing those aliquots at −20 °C. Researchers have documented that each freeze-thaw cycle damages peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one bulk vial multiple times. Thaw individual aliquots overnight in a refrigerator and use within a few days of thaw.
The reconstitution diluent is USP-grade bacteriostatic water containing 0.9% benzyl alcohol; see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Class | Documented mechanism (clinical research) | Format at Ronin |
|---|---|---|---|
| Tirzepatide | Dual GLP-1/GIP receptor agonist (biased toward GIP) | Two-receptor agonism with biased GIP-receptor activation; once-weekly subcutaneous dosing | 10 mg vial |
| Semaglutide | GLP-1 receptor mono-agonist | Single-receptor agonism; pulsatile activation supports glucose-dependent insulin release, glucagon suppression, gastric-emptying delay, appetite modulation | 10 mg vial |
Tirzepatide sits at the dual-agonist position in the GLP-1-class research peptide spectrum, between Semaglutide (mono) (triple). The Frías 2021 SURPASS-2 head-to-head trial against Semaglutide (PMID 34170647) and the Karagiannis 2024 systematic review and network meta-analysis (PMID 38613667) anchor the cross-class comparison literature. the cagrilintide-and-semaglutide combination sits in a different mechanistic neighbourhood, pairing Semaglutide's GLP-1 mono-agonism with amylin-pathway agonism via Cagrilintide.
Reconstitution and laboratory handling
A 10 mg tirzepatide vial reconstituted with 2 mL of bacteriostatic water yields a working concentration of 5 mg/mL. Alternative dilutions: 1 mL gives 10 mg/mL (concentrated stock); 4 mL gives 2.5 mg/mL (dilute stock).
Reconstitution procedure:
- Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water down the inner wall of the peptide vial as it goes in — never onto the lyophilized cake itself, which would foam and damage peptide structure at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent. If hazy, treat as degraded or contaminated and discard.
For concentration math across different reconstitution volumes, the Ronin peptide reconstitution calculator has tirzepatide pre-loaded as a preset.
Frequently asked questions
What is Tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that engages two metabolic receptors simultaneously — the GIP receptor and the GLP-1 receptor — making it the first dual-incretin-receptor agonist to enter widespread clinical research. The compound's backbone derives from native human GIP, with engineered modifications adding GLP-1 receptor activity and supporting once-weekly subcutaneous dosing. Investigators have studied the compound across the SURPASS Phase 3 program in type 2 diabetes, the SURMOUNT Phase 3 program in obesity, and 2024–2025 Phase 3 trials in MASLD, obstructive sleep apnea, and HFpEF. Ronin Peptides offers tirzepatide as a research-grade laboratory reagent; it is sold for bench use only and is not intended for human or veterinary administration.
What does dual GIP/GLP-1 agonism contribute beyond GLP-1 mono-agonism?
GIP receptor activation contributes additional insulin secretion at the pancreatic beta cell beyond what GLP-1 alone produces, and engages adipose-tissue effects that GLP-1 mono-agonists do not. The Willard 2020 mechanism paper documented that tirzepatide is biased toward GIP receptor activation more than GLP-1 receptor activation — an unusual feature for a designed dual agonist. The Frías 2021 SURPASS-2 head-to-head trial against semaglutide demonstrated larger HbA1c and weight reductions for tirzepatide at all dose tiers, an outcome researchers attribute to the additional GIP-receptor arm contribution (PMID 32730231, PMID 34170647).
What is the regulatory status of Tirzepatide?
Tirzepatide is a long-acting dual GIP/GLP-1 receptor agonist studied for its effects on weight management, glucose regulation, and cardiometabolic health. It is one of the most extensively researched incretin-based peptides with wide clinical use.
Tirzepatide is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is Tirzepatide verified?
Each batch passes through Janoshik Analytical, an independent peptide-analytics lab, for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com, so researchers can confirm the certificate's authenticity without trusting the manufacturer's word alone. To pull the COA covering the batch on your order, email support@roninpeptides.ca with your order number; the typical reply turnaround is well under 24 hours.
How is Tirzepatide reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 10 mg vial, producing a 5 mg/mL solution. Direct the water down the inner wall of the vial as it goes in — never onto the lyophilized cake itself. Swirl gently or invert slowly until fully dissolved. Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for concentration math across different reconstitution volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch.
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231 | doi:10.1172/jci.insight.140532
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. PMID: 33236115 | doi:10.1210/clinem/dgaa863
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647 | doi:10.1056/NEJMoa2107519
- Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824. PMID: 34672967 | doi:10.1016/S0140-6736(21)02188-7
- Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: SURPASS-5. JAMA. 2022;327(6):534-545. PMID: 35133415 | doi:10.1001/jama.2022.0078
- Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2022;10(6):393-406. PMID: 35468325 | doi:10.1016/S2213-8587(22)00070-5
- Nauck MA et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. PMID: 36050763 | doi:10.1186/s12933-022-01604-7
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275 | doi:10.1016/S0140-6736(23)01200-X
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-4. JAMA. 2024;331(1):38-48. PMID: 38078870 | doi:10.1001/jama.2023.24945
- France NL et al. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024;84(2):227-238. PMID: 38388874 | doi:10.1007/s40265-023-01992-4
- Karagiannis T et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2024;67(7):1206-1222. PMID: 38613667 | doi:10.1007/s00125-024-06144-1
- Zhao L et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: SURMOUNT-CN. JAMA. 2024;332(7):551-560. PMID: 38819983 | doi:10.1001/jama.2024.9217
- Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PMID: 38856224 | doi:10.1056/NEJMoa2401943
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654 | doi:10.1056/NEJMoa2404881
- Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. PMID: 39555826 | doi:10.1056/NEJMoa2410027
